Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis

Sonja Holm-Yildiz; Tina Dysgaard; Thomas Krag; Britt Stævnsbo Pedersen; Sebastian Rask Hamm; Laura Pérez-Alós; Cecilie Bo Hansen; Mia Marie Pries-Heje; Line Dam Heftdal; Rasmus Bo Hasselbalch; Kamille Fogh; Johannes Roth Madsen; Ruth Frikke-Schmidt; Linda Maria Hilsted; Erik Sørensen; Sisse Rye Ostrowski; Henning Bundgaard; Peter Garred; Kasper Iversen; Susanne Dam Nielsen; John Vissing

doi:10.1016/j.jneuroim.2023.578215

Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis

Sonja Holm-Yildiz^*, Tina Dysgaard, Thomas Krag, Britt Stævnsbo Pedersen, Sebastian Rask Hamm, Laura Pérez-Alós, Cecilie Bo Hansen, Mia Marie Pries-Heje, Line Dam Heftdal, Rasmus Bo Hasselbalch, Kamille Fogh, Johannes Roth Madsen, Ruth Frikke-Schmidt, Linda Maria Hilsted, Erik Sørensen, Sisse Rye Ostrowski, Henning Bundgaard, Peter Garred, Kasper Iversen, Susanne Dam NielsenJohn Vissing

^*Corresponding author for this work

Abstract

We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).

Original language	English
Article number	578215
Journal	Journal of Neuroimmunology
Volume	384
ISSN	0165-5728
DOIs	https://doi.org/10.1016/j.jneuroim.2023.578215
Publication status	Published - Nov 2023

Access to Document

10.1016/j.jneuroim.2023.578215Licence: CC BY

Cite this

Holm-Yildiz, S., Dysgaard, T., Krag, T., Pedersen, B. S., Hamm, S. R., Pérez-Alós, L., Hansen, C. B., Pries-Heje, M. M., Heftdal, L. D., Hasselbalch, R. B., Fogh, K., Madsen, J. R., Frikke-Schmidt, R., Hilsted, L. M., Sørensen, E., Ostrowski, S. R., Bundgaard, H., Garred, P., Iversen, K., ... Vissing, J. (2023). Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis. Journal of Neuroimmunology, 384, Article 578215. https://doi.org/10.1016/j.jneuroim.2023.578215

Holm-Yildiz, S , Dysgaard, T , Krag, T , Pedersen, BS , Hamm, SR, Pérez-Alós, L, Hansen, CB, Pries-Heje, MM, Heftdal, LD, Hasselbalch, RB, Fogh, K, Madsen, JR, Frikke-Schmidt, R , Hilsted, LM , Sørensen, E , Ostrowski, SR , Bundgaard, H , Garred, P , Iversen, K , Nielsen, SD & Vissing, J 2023, 'Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis', Journal of Neuroimmunology, vol. 384, 578215. https://doi.org/10.1016/j.jneuroim.2023.578215

@article{54ed4467454046b3a1a7bfb450e8d508,

title = "Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis",

abstract = "We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).",

author = "Sonja Holm-Yildiz and Tina Dysgaard and Thomas Krag and Pedersen, {Britt St{\ae}vnsbo} and Hamm, {Sebastian Rask} and Laura P{\'e}rez-Al{\'o}s and Hansen, {Cecilie Bo} and Pries-Heje, {Mia Marie} and Heftdal, {Line Dam} and Hasselbalch, {Rasmus Bo} and Kamille Fogh and Madsen, {Johannes Roth} and Ruth Frikke-Schmidt and Hilsted, {Linda Maria} and Erik S{\o}rensen and Ostrowski, {Sisse Rye} and Henning Bundgaard and Peter Garred and Kasper Iversen and Nielsen, {Susanne Dam} and John Vissing",

year = "2023",

month = nov,

doi = "10.1016/j.jneuroim.2023.578215",

language = "English",

volume = "384",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis

AU - Holm-Yildiz, Sonja

AU - Dysgaard, Tina

AU - Krag, Thomas

AU - Pedersen, Britt Stævnsbo

AU - Hamm, Sebastian Rask

AU - Pérez-Alós, Laura

AU - Hansen, Cecilie Bo

AU - Pries-Heje, Mia Marie

AU - Heftdal, Line Dam

AU - Hasselbalch, Rasmus Bo

AU - Fogh, Kamille

AU - Madsen, Johannes Roth

AU - Frikke-Schmidt, Ruth

AU - Hilsted, Linda Maria

AU - Sørensen, Erik

AU - Ostrowski, Sisse Rye

AU - Bundgaard, Henning

AU - Garred, Peter

AU - Iversen, Kasper

AU - Nielsen, Susanne Dam

AU - Vissing, John

PY - 2023/11

Y1 - 2023/11

N2 - We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).

AB - We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).

UR - http://www.scopus.com/inward/record.url?scp=85172764956&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2023.578215

DO - 10.1016/j.jneuroim.2023.578215

M3 - Journal article

C2 - 37797472

SN - 0165-5728

VL - 384

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

M1 - 578215

ER -

Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this